Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$69.00 USD

69.00
3,405,133

-0.70 (-1.00%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks News

What's in Store for Edwards Lifesciences' (EW) Q4 Earnings?

Edwards Lifesciences (EW) expected to see consistent performance by Surgical Structural Heart and Critical Care segments in Q4.

Will Flagship Impella Drive ABIOMED's (ABMD) Q3 Earnings?

ABIOMED (ABMD) is likely to gain from flagship Impella in third-quarter fiscal 2019; positive trends in the CHD markets buoy optimism.

NextGen's (NXGN) Q3 Earnings Beat Estimates, Bookings Up Y/Y

NextGen (NXGN) delivers strong growth in software, hardware and other non-recurring revenues in Q3; strong fiscal 2019 view buoys optimism.

What's Setting the Tone for Hologic's (HOLX) Q1 Earnings?

Strength in the Breast Health business, Panther system and international business is likely to boost Hologic's (HOLX) top line in Q1.

Will Core Renal Care Unit Fuel Baxter's (BAX) Q4 Earnings?

Management at Baxter (BAX) expects Renal Care to see growth of 3-4% in 2018.

Varian (VAR) Meets Q1 Earnings Estimates, Grows Globally

Solid overseas growth boosts Varian's (VAR) fiscal Q1 results.

PetMed (PETS) Q3 Earnings Fall Y/Y, Reorder Sales Strong

PetMed (PETS) sees reorder sales growth in Q3. Rising competition forced the company to offer additional discounts to customers in the quarter which had a negative impact on the gross margin.

Abbott (ABT) Q4 Earnings Meet Estimates, Organic Growth Solid

Within Structural Heart, growth is driven by several product areas across Abbott's (ABT) broad portfolio.

Can Diagnostic Revenues Fuel PerkinElmer's (PKI) Q4 Earnings?

PerkinElmer's (PKI) fourth-quarter 2018 results are likely to benefit from the Diagnostics Segment's solid performance.

Can Overall Growth Fuel Align Technology's (ALGN) Q4 Earnings?

Align Technology (ALGN) is likely to gain from strength in Invisalign space as well as Scanner and Service business in fourth-quarter 2018.

ResMed Launches Nasal Mask Devise, Extends AirFit Portfolio

ResMed's (RMD) AirFit N30i with a top-of-head connection keeps tubing out of the wearers' way, thus letting them conveniently move and sleep in any position.

Will Core MedSurg Segment Aid Stryker's (SYK) Q4 Earnings?

Stryker's (SYK) Q4 results are likely to be aided by its core MedSurg segment.

Here's Why Momentum Investors Will Love DexCom (DXCM)

Does DexCom (DXCM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?

Is (DXCM) Outperforming Other Medical Stocks This Year?

Will Instruments Fuel Intuitive Surgical (ISRG) Q4 Earnings?

Intuitive Surgical's (ISRG) top line in the fourth quarter of 2018 is likely to benefit from solid grow that the Instruments and Accessories segment.

Varian Medical (VAR) to Report Q1 Earnings: What's in Store?

Strong overseas presence and product launches are likely to aid Varian Medical's (VAR) fiscal first-quarter results.

Sreyoshi Mukherjee headshot

3 Medical Services Stocks to Buy in 2019: HQY, AMEH & OPGN

Here we discuss three profitable Medical Services stocks as the industry booms.

AngioDynamics (ANGO) Q2 Earnings Beat on Gains From NanoKnife

AngioDynamics (ANGO) sees a solid fiscal second quarter; gains from strong segmental contributions.

Here's Why Investors Should Bet on DexCom (DXCM) Right Now

A solid guidance for 2018 and lucrative deals make DexCom (DXCM) a promising investment pick.

Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?

Is (DXCM) Outperforming Other Medical Stocks This Year?

DexCom Sees Hammer Chart Pattern: Time to Buy?

DexCom has been struggling lately, but the selling pressure may be coming to an end soon.

Sapna Bagaria headshot

4 Healthcare Stocks That Popped More Than 100% in 2018

Players in the Healthcare sector gained from aging population, expanding government business, technological investment, strong demand for its product and services and industry consolidation.

Are ABMD & DXCM Neck and Neck? Let's Take a Closer Look

DexCom (DXCM) scores higher than Abiomed (ABMD) when it comes to current-year revenue projections and fundamentals.

Sweta Jaiswal headshot

4 Medical Device Stocks That More Than Doubled in 2018

Here are four medical device stocks which have performed really well in 2018 and should be on investors' radar next year as well.

Sreyoshi Mukherjee headshot

5 Stocks That Popped More Than 100% in 2018 Defying All Odds

Five solid picks that defied the problems confronting the U.S. economy.